Lapatinib combined with capecitabine

Lapatinib and capecitabine (Capecitabine) are a common combination therapy used to treat HER2 positive breast cancer, especially in the setting of advanced or metastatic breast cancer. This combined treatment regimen has been widely used in clinical practice and has achieved remarkable results.

The following is important information about lapatinib and capecitabine combination therapy:

1.Mechanism: This combination treatment regimen combines two different drugs with different mechanisms of action to improve the therapeutic effect.

2.Lapatinib: Lapatinib is a targeted therapy drug that interferes with the growth signaling of cancer cells by inhibiting the activity of HER2 receptors and EGFR receptors. This helps stop the growth and spread ofHER2positive breast cancer cells.

3.Capecitabine: Capecitabine is a chemotherapy drug that is similar to fluorouracil and can interfere with the synthesis and replication of DNA in cancer cells, leading to the death of cancer cells.

4.Indications: This combination treatment is often used for HER2positive breast cancer, especially in the treatment of locally advanced or metastatic breast cancer. It helps prolong patient survival and reduce symptoms.

5.Treatment cycle: The specific treatment cycle and dose will be determined based on the patient's specific situation, doctor's recommendations and the stage of the disease. Patients need regular monitoring and follow-up with their doctor to ensure treatment effectiveness and manage possible side effects.

6.Side effects: This combination treatment may cause some side effects, including but not limited to diarrhea, skin rash, nausea, vomiting, fatigue, oral ulcers, etc. Patients need to work closely with their doctor to report any discomfort or side effects so that their treatment plan can be promptly addressed and adjusted.

7.Therapeutic effect: Clinical studies and actual clinical experience show that the combined use of lapatinib and capecitabine can significantly improve the survival rate of HER2 positive breast cancer patients. This combination treatment regimen has become an important choice for first-line and later-line treatment.

Lapatinib is already on the market in China, but it has not yet been included in medical insurance. Patients can purchase it domestically at a price of around 5,000 to 6,000 yuan. Please consult the local hospital pharmacy for specific prices. There are original lapatinib drugs and generic drugs abroad. The original drug is cheaper than the original drug in Türkiye, which costs more than 2,000 yuan. Generic drugs include Indian generic drugs and Bangladeshi generic drugs, and the price is around a few hundred yuan. The ingredients of domestic original drugs, foreign original drugs and generic drugs are basically the same.